Hydromethylthionine

Hydromethylthionine

SCHEMBL109756

CN(C)c1ccc2c(c1)Sc1cc(N(C)C)ccc1N2

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SNCA P37840 8/20 0.50
MAPT P10636 5/20 0.48
NOX1 Q9Y5S8 5/20 0.43
GAA P10253 3/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
TDP1 Q9NUW8 3/20 0.43
MAPK1 P28482 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ALOX15 P16050 2/20 0.41
CYP1A2 P05177 1/20 0.41
BCHE P06276 1/20 0.41
POLB P06746 1/20 0.41
CYP3A4 P08684 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
ALOX12 P18054 1/20 0.41
MAOA P21397 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydromethylthionine SCHEMBL12592446 1.00 SNCA (0.50) SNCAMAPTNOX1GAAMEN1
Hydromethylthionine SCHEMBL29356148 1.00 SNCA (0.50) SNCAMAPTNOX1GAAMEN1
Hydromethylthionine SCHEMBL31159644 0.98 SNCA (0.48) SNCAMAPTNOX1GAAMEN1
Hydromethylthionine SCHEMBL1577040 0.98 SNCA (0.48) SNCAMAPTNOX1GAAMEN1
Hydromethylthionine SCHEMBL31159649 0.98 SNCA (0.48) SNCAMAPTNOX1GAAMEN1
Hydromethylthionine SCHEMBL23683393 0.98 SNCA (0.48) SNCAMAPTNOX1GAAMEN1
Hydromethylthionine SCHEMBL12470963 0.98 SNCA (0.48) SNCAMAPTNOX1GAAMEN1
Hydromethylthionine SCHEMBL25194477 0.98 SNCA (0.48) SNCAMAPTNOX1GAAMEN1
Hydromethylthionine SCHEMBL25199191 0.98 SNCA (0.48) SNCAMAPTNOX1GAAMEN1
Hydromethylthionine SCHEMBL31159642 0.98 SNCA (0.48) SNCAMAPTNOX1GAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12410394-B2 Composition comprising nicotinamide mononucleotide and leucomethylene blue ATHERGEN, INC. (US) 2025-09-09 US claimed
US-20250276046-A1 SELF-ASSEMBLING OXYGEN CARRIER COMPOSITIONS KaloCyte (US) 2025-09-04 US claimed
US-20250268935-A1 Tumor Treatment SIESS HAROLD E (US) 2025-08-28 US claimed
EP-4313156-B1 DISULFIDE-BASED PRODRUG COMPOUNDS UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) 2025-08-06 EP claimed
US-20250235468-A1 FORMULATION OF LONG-ACTING LEVONORGESTREL BUTANOATE INJECTABLE DEPOT SUSPENSION EASTERN VIRGINIA MEDICAL SCHOOL 2025-07-24 US claimed
WO-2025129232-A1 METHODS AND DEVICES FOR MEASURING ANTIOXIDANT ACTIVITY IN A FLUID SAMPLE Memphasys Limited (AU) 2025-06-26 WO claimed
US-20250161323-A1 FORMULATION OF LONG-ACTING LEVONORGESTREL BUTANOATE INJECTABLE DEPOT SUSPENSION EASTERN VIRGINIA MEDICAL SCHOOL 2025-05-22 US claimed
WO-2025101956-A2 CONTROL OF ENZYMATIC NUCLEIC ACID SYNTHESIS VIA ELECTROCHEMICAL MEANS THE CHARLES STARK DRAPER LABORATORY, INC. (US) 2025-05-15 WO claimed
US-12290523-B2 Formulation of long-acting levonorgestrel butanoate injectable depot suspension EASTERN VIRGINIA MEDICAL SCHOOL (US) 2025-05-06 US claimed
US-12257289-B2 Self-assembling oxygen carrier compositions KaloCyte, Inc. (US) 2025-03-25 US claimed
WO-1995013079-A1 METHYLENE BLUE FOR THE TREATMENT OR PROPHYLAXIS OF ANCEPHALOPATHY CAUSED BY IFOSFAMIDE NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) 1995-05-18 WO claimed
US-5384248-A Process for measuring an analyte with an oxidase and an oxidizable color reagent and surfactants WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 1995-01-24 US claimed
EP-0402094-A2 Process for measuring body fluid components WAKO PURE CHEMICAL INDUSTRIES LTD (JP) 1990-12-12 EP claimed
EP-0097220-B1 THE STABILIZATION OF LEUCOMETHYLENE BLUE DYES ON A PRINTING SUBSTRATE International Business Machines Corporation (US) 1988-06-08 EP claimed
EP-0113151-B1 PRINTING MEDIUM AND USE THEREOF International Business Machines Corporation (US) 1988-03-09 EP claimed
US-4505399-A Tamper-indicating device and method WEINER ROBERT C 1985-03-19 US claimed
EP-0113151-A2 Printing medium and use thereof International Business Machines Corporation (US) 1984-07-11 EP claimed
US-4443302-A Printing medium and use thereof INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 1984-04-17 US claimed
EP-0097220-A2 The stabilization of leucomethylene blue dyes on a printing substrate International Business Machines Corporation (US) 1984-01-04 EP claimed
US-4017313-A Photosensitive composition containing a leuco dye, a photosensitizer, an aromatic aldehyde and a secondary or tertiary amine and the use thereof in a direct-print process E. I. DU PONT DE NEMOURS AND COMPANY (US) 1977-04-12 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12257289-B2 Self-assembling oxygen carrier compositions HBG2, HBG1, HBB SNCA 3800/4885MAPT 4023/4885NOX1 2129/4885
US-20250276046-A1 SELF-ASSEMBLING OXYGEN CARRIER COMPOSITIONS HBG2, HBG1, HBB SNCA 3800/4885MAPT 4023/4885NOX1 2129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.